Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Jones, L P; Tilli, M T; Assefnia, S; Torre, K; Halama, E D; Parrish, A; Rosen, E M; Furth, P A

Jones, L P; Tilli, M T; Assefnia, S; Torre, K; Halama, E D; Parrish, A; Rosen, E M; Furth, P A.

Affiliation

Jones LP; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.

Oncogene ; 27(6): 794-802, 2008 Jan 31.

Article in En | MEDLINE | ID: mdl-17653086

Subject(s)

BRCA1 Protein/genetics; Estrogen Receptor alpha/metabolism; Estrogens/metabolism; Mammary Neoplasms, Experimental/pathology; Precancerous Conditions/pathology; Animals; Cell Proliferation; Estrogen Receptor alpha/analysis; Estrogens/pharmacology; Female; Mammary Neoplasms, Experimental/genetics; Mammary Neoplasms, Experimental/metabolism; Mice; Mice, Mutant Strains; Neoplasm Invasiveness; Precancerous Conditions/genetics; Precancerous Conditions/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precancerous Conditions / BRCA1 Protein / Estrogen Receptor alpha / Estrogens / Mammary Neoplasms, Experimental Limits: Animals Language: En Journal: Oncogene Year: 2008 Document type: Article

Fulltext

XML

PubMed Links

Search on Google